Skip to main content
TipRanks
Go Ultimate75% OFF

Scinai Immunotherapeutics (SCNI) Stock Statistics & Valuation Metrics

351 Followers

Total Valuation

Scinai Immunotherapeutics has a market cap or net worth of $504.08K. The enterprise value is $8.12M.

Market Cap
$504.08K
Enterprise Value
$8.12M

Share Statistics

Scinai Immunotherapeutics has 1,353,228 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
1,353,228
Owned by Insiders
―
Owned by Institutions
0.37%

Financial Efficiency

Scinai Immunotherapeutics’s return on equity (ROE) is -1.03 and return on invested capital (ROIC) is -72.73%.

Return on Equity (ROE)
-1.03
Return on Assets (ROA)
-0.71
Return on Invested Capital (ROIC)
-72.73%
Return on Capital Employed (ROCE)
-0.75
Revenue Per Employee
29.13K
Profits Per Employee
-184.60K
Employee Count
45
Asset Turnover
0.11
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Scinai Immunotherapeutics is 0.00. Scinai Immunotherapeutics’s PEG ratio is 0.00.

PE Ratio
0.00
PS Ratio
0.07
PB Ratio
0.01
Price to FCF
-0.03
Price to Operating Cash Flow
-0.01
PEG Ratio
0.00

Income Statement

In the last 12 months, Scinai Immunotherapeutics had revenue of 1.31M and earned -8.31M in profits. Earnings per share was -36.00.

Revenue
1.31M
Gross Profit
-2.65M
Operating Income
-7.54M
Pretax Income
-8.31M
Net Income
-8.31M
EBITDA
-6.53M
Earnings Per Share (EPS)
-36.00

Cash Flow

In the last 12 months, operating cash flow was -7.55M and capital expenditures -236,807, giving a free cash flow of -7.79M billion.

Operating Cash Flow
-7.55M
Free Cash Flow
-7.79M
Free Cash Flow per Share
-32.38

Dividends & Yields

Scinai Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-4044.99%
Earnings Yield
-2816.62%

Stock Price Statistics

Beta
1.36
52-Week Price Change
-96.13%
50-Day Moving Average
1.09
200-Day Moving Average
3.86
Relative Strength Index (RSI)
23.81
Average Volume (3m)
2.16M

Important Dates

Scinai Immunotherapeutics upcoming earnings date is May 13, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
May 13, 2027
Ex-Dividend Date
―

Financial Position

Scinai Immunotherapeutics as a current ratio of 1.30, with Debt / Equity ratio of 27.98%

Current Ratio
1.30
Quick Ratio
1.30
Debt to Market Cap
0.18
Net Debt to EBITDA
-0.09
Interest Coverage Ratio
-21.01

Taxes

In the past 12 months, Scinai Immunotherapeutics has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Scinai Immunotherapeutics EV to EBITDA ratio is -0.29, with an EV/FCF ratio of -0.24.

EV to Sales
0.61
EV to EBITDA
-0.29
EV to Free Cash Flow
-0.24
EV to Operating Cash Flow
-0.25

Balance Sheet

Scinai Immunotherapeutics has $1.71M in cash and marketable securities with $3.39M in debt, giving a net cash position of -$1.68M billion.

Cash & Marketable Securities
$1.71M
Total Debt
$3.39M
Net Cash
-$1.68M
Net Cash Per Share
-$1.24
Tangible Book Value Per Share
$44.54

Margins

Gross margin is -119.47%, with operating margin of -275.36%, and net profit margin of -81.92%.

Gross Margin
-119.47%
Operating Margin
-275.36%
Pretax Margin
-81.92%
Net Profit Margin
-81.92%
EBITDA Margin
-212.80%
EBIT Margin
-275.36%

Analyst Forecast

The average price target for Scinai Immunotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
143.06%
EPS Growth Forecast
94.98%

Scores

Smart Score
―
AI Score
42